Physician

Christopher S.r. Dakhil, M.D.

According to 2025 Medicare claims, Christopher Dakhil, M.D. (NPI: 1972721348) practices hematology/oncology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67214-3728. Dakhil is affiliated with the Aledade 155 National MSSP (ACO ID: A5358) and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Dakhil's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,413 traditional Medicare patients, billed 465,501 HCPCS/CPT codes, and received $9,160,712 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,959 prescription claims across 339 beneficiaries totaling $2,817,447 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 13 claims. Open Payments data shows 190 records totaling $4,814. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,476,324 to $9,160,712. Similarly, Part D prescription costs have moved sharply higher in recent years, from $653,521 to $2,817,447. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,924 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	845	178,516	$2,476,324
2016	1,032	325,247	$3,433,763
2017	1,123	329,390	$3,962,684
2018	1,220	273,460	$4,395,815
2019	1,255	306,337	$4,845,374
2020	1,163	306,181	$4,820,514
2021	939	266,236	$4,288,662
2022	1,181	320,446	$5,558,223
2023	1,447	371,407	$6,606,743
2024	1,413	465,501	$9,160,712

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	165	1,056	$653,521
2016	208	1,327	$555,315
2017	234	1,372	$408,888
2018	272	1,641	$740,756
2019	282	1,721	$1,477,983
2020	275	1,536	$1,806,784
2021	257	1,437	$878,261
2022	323	1,628	$1,661,917
2023	348	1,887	$2,668,853
2024	339	1,959	$2,817,447

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	76	206	$18,098
2016	N/R	98	$7,144
2017	N/R	59	$4,430
2018	N/R	46	$3,417
2019	N/R	23	$1,258
2020	N/R	N/R	N/R
2021	11	13	$1,428
2022	12	13	$1,612
2023	11	25	$3,571
2024	N/R	13	$2,007

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	314	1,035	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	452	608	$57
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	534	878	$12
96372	Injection of drug or substance under skin or into muscle	325	916	$10
36415	Insertion of needle into vein for collection of blood sample	337	1,088	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	38	1,140	$463,943
Ibrance	Palbociclib	25	700	$394,314
Imbruvica	Ibrutinib	25	700	$384,021
Cabometyx	Cabozantinib S-Malate	12	360	$271,039
Venclexta	Venetoclax	25	729	$263,293

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$2,007

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	190	$4,814	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher S.r. Dakhil, M.D.?

Tedicare shows public-source Medicare data for Christopher S.r. Dakhil, M.D. (NPI 1972721348), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher S.r. Dakhil, M.D. have ACO affiliation data?

Christopher S.r. Dakhil, M.D. is shown with ACO affiliation data for Aledade 155 National MSSP (MSSP, ACO ID A5358) and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Christopher S.r. Dakhil, M.D.?

Christopher S.r. Dakhil, M.D. is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Christopher S.r. Dakhil, M.D. have Open Payments data?

Christopher S.r. Dakhil, M.D. has 190 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.